Kidney cancer is one of the most common cancers among men and women. Its incidence has been increasing during the last two decades, accounting for 2%-3% of all new tumor cases. 1 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. were associated with a poor prognosis in KIRC, and IDO1 and PD-L2 were associated with a poor prognosis in KIRP. This study indicates TIICs are important determinants of prognosis in RCC meanwhile reveals potential targets and biomarkers for immunotherapy development.
Immune infiltration of tumors is closely associated with clinical outcome in renal cell carcinoma (RCC). Tumor-infiltrating immune cells (TIICs) regulate cancer progression and are appealing therapeutic targets. The purpose of this study was to determine the composition of TIICs in RCC and further reveal the independent prognostic values of TIICs. CIBERSORT, an established algorithm, was applied to estimate the proportions of 22 immune cell types based on gene expression profiles of 891 tumors.
Cox regression was used to evaluate the association of TIICs and immune checkpoint modulators with overall survival (OS). We found that CD8+ T cells were associated with prolonged OS (hazard ratio [HR] = 0.09, 95% confidence interval [CI] .01-.53; P = 0.03) in chromophobe carcinoma (KICH). A higher proportion of regulatory T cells was associated with a worse outcome (HR = 1.59, 95% CI 1.23-.06; P < 0.01) in renal clear cell carcinoma (KIRC). In renal papillary cell carcinoma (KIRP), M1 macrophages were associated with a favorable outcome (HR = .43, 95% CI .25-.72; P < 0.01), while M2 macrophages indicated a worse outcome (HR = 2.55, 95% CI 1.45-4.47; P < 0.01). Moreover, the immunomodulator molecules CTLA4 and LAG3
were associated with a poor prognosis in KIRC, and IDO1 and PD-L2 were associated with a poor prognosis in KIRP. This study indicates TIICs are important determinants of prognosis in RCC meanwhile reveals potential targets and biomarkers for immunotherapy development.
K E Y W O R D S
genomic alterations, overall survival, prognosis, renal cell carcinoma, tumor-infiltrating immune cells of RCC remains unsatisfactory. 5, 6 As a well-known heterogeneous disease, the useful biomarkers which contribute to individualized treatment options are still lacking for RCC, especially in current immunotherapy. 20 Both TAM and T cell phenotypes are appealing biomarkers in cancer. 21, 22 Tumor-infiltrating immune cells are likely to be effective targets for drugs to improve clinical outcomes. Recently, drug trials targeting immune checkpoints reported a great improvement in patient survival, including for RCC patients. 6 Nivolumab, a checkpoint blocker, has been approved for RCC treatment, improving treatment prospects. 23 With growing attention on immune checkpoint therapy, the distribution of TIIC has become a main research focus. Previous studies estimated the composition of TIIC by flow cytometry and immunohistochemistry (IHC). 24 These methods can only analyze a few immune cell types at once and are restricted by the number of fluorescent channels available. However, the immune response requires numerous different cell types to coordinately interact.
To accurately study the interaction of immune responses, a large number of samples should be analyzed. Recently, a bioinformatics tool, CIBERSORT, was developed. [25] [26] [27] This deconvolution algorithm based on gene expression data quantifies the cellular composition of immune response and has greatly expanded the potential of the genomic database. Due to the superiority of CIBERSORT over other methods, it has received increasing attention and it has been successfully used to evaluate the composition of immune cells in breast, lung and liver cancer. 25, 28, 29 In this study, CIBERSORT was applied to assess the relative proportions of 22 TIIC, presenting a comprehensive immune cell landscape of RCC. We further revealed relationships between the composition of TIIC and molecular subtypes, tumor stages, and survival in RCC; moreover, we explored the association between TIIC and recurrent genomic alterations. In addition, the prognostic landscape of immune checkpoint modulators was investigated in KIRC and KIRP. The present study attempted to reveal potential targets and biomarkers for immunotherapy of RCC.
| MATERIAL S AND ME THODS

| Data acquisition
Data from the public domain were used in the current study. 
| Assessment of immune infiltration
| Statistical analysis
Statistical analyses were conducted using R v3. 
| RE SULTS
| Summary of renal cell carcinoma clinicopathological information from 891 cases
In this study, the dataset included 891 cases of RCC samples. The clinicopathological characteristics of these samples are shown in Table 1 . 
| Distribution of tumor-infiltrating immune cells
| Association between tumor-infiltrating immune cells and genomic alterations
| Association between tumor-infiltrating immune cells and survival
The prognostic value of TIIC was assessed in RCC. In Figure 4 , the blue bubble indicates that a higher level is related to prolonged F I G U R E 2 Associations between the composition of tumor-infiltrating immune cells and copy number of aberrations in renal cell carcinoma cohort (n = 881). *P < 0.05, **P < 0.01 OS and the red bubble indicates that a higher level is related to shorter OS. Detailed results are provided in Tables S1-S3. CD8+   T cells 
| Expression of immunomodulators and their prognostic significance in renal cell carcinoma
Immune checkpoint blockade therapy has significantly improved the treatment prospects of refractory RCC. We revealed differences in the expressions of several critical immunomodulators between tumor and normal tissues. These immunomodulators included costimulatory molecules (CD27 and ICOS) and co-inhibitory molecules (PD-1, TIM-3, LAG3, PDL1, CTLA4, PD-L2, TIGIT and IDO1). As shown in Figure 5 , the expression of PD-1, PD-L1, CTLA4, TIM-3, IDO1 and PD-L2 were significantly increased in tumors. In addition,
we evaluated the prognostic value of immune checkpoint molecules that participate in immune escape mechanisms. In KIRC, patients 
| D ISCUSS I ON
We conducted a comprehensive and detailed assessment of immune infiltration in RCC, based on the deconvolution of bulk gene expression data from a large set of samples. In addition, the independent prognostic value of immune phenotypes was revealed. This should be of great interest in view of the current development of immunomodulatory therapies. We reported that the composition of TIIC differs greatly in various subtypes and stages of RCC. These differences may be important determinants for prognosis.
The importance of immune infiltration for prognosis has been recognized. The immunoscore, a scoring system that evaluates the distribution and amount of TIIC in tumors, has been applied to colon cancer and has shown prognostic value. 30 Here, we found that a high Here, the association between TIIC and genomic alterations was revealed. Tumors presenting with TP53 mutations were associated with higher levels of resting memory CD4+ T cells and CD8+ T cells. A similar association was also observed for tumors with ARID1A mutations. Although we found no evidence for an association of TP53 mutations and TIIC in RCC, a study of ovarian cancer showed that TP53 mutations were associated with a high amount of tumor-infiltrating lymphocytes. 38 Previous studies reported that a deficiency in ARID1A promoted the infiltration of immune cells in hepatocellular carcinoma. 39, 40 Moreover, ARID1A mutations are associated with high immune infiltration and microsatellite instability in colorectal cancer. 40 In addition, copy number variations (CNV) are another common form of genetic instability, and directly change the expression level of specific genes. We observed a higher level of CD8+ T cells in tumors with chr1q32.2 gain (including G0S2). G0S2 can modulate homeostatic proliferation of CD8+ T cells. 41 The CAN of chr1q32.2 may affect the immune infiltration of CD8+ T cells by regulating the expression of G0S2. Our results showed a lower level of resting mast cells in tumors with chr3p21.31 loss (including SETD2). Moreover, SETD2 has been reported in association with immune infiltration in KIRP. 42 Although we have some knowledge of the clinical utility of mutations, the value of genomic alterations as biomarkers for immunotherapy requires further research.
We also revealed the independent prognostic value of several important immune checkpoint modulators in KIRC and KIRP.
Blocking immune checkpoints is currently the most promising strategy for cancer immunotherapy. 43 Our results showed that CTLA4, LAG3 and TIGIT were associated with a worse prognosis in KIRC, 
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